Engineered Nanoparticles for Drug Delivery in Cancer Therapy
The DOI matches its Crossref record; 579 of the 579 references it cites were found in a registry or an index.
Abstract
In medicine, nanotechnology has sparked a rapidly growing interest as it promises to solve a number of issues associated with conventional therapeutic agents, including their poor water solubility (at least, for most anticancer drugs), lack of targeting capability, nonspecific distribution, systemic toxicity, and low therapeutic index. Over the past several decades, remarkable progress has been made in the development and application of engineered nanoparticles to treat cancer more effectively. For example, therapeutic agents have been integrated with nanoparticles engineered with optimal sizes, shapes, and surface properties to increase their solubility, prolong their circulation half‐life, improve their biodistribution, and reduce their immunogenicity. Nanoparticles and their payloads have also been favorably delivered into tumors by taking advantage of the pathophysiological conditions, such as the enhanced permeability and retention effect, and the spatial variations in the pH value. Additionally, targeting ligands (e.g., small organic molecules, peptides, antibodies, and nucleic acids) have been added to the surface of nanoparticles to specifically target cancerous cells through selective binding to the receptors overexpressed on their surface. Furthermore, it has been demonstrated that multiple types of therapeutic drugs and/or diagnostic agents (e.g., contrast agents) could be delivered through the same carrier to enable combination therapy with a potential to overcome multidrug resistance, and real‐time readout on the treatment efficacy. It is anticipated that precisely engineered nanoparticles will emerge as the next‐generation platform for cancer therapy and many other biomedical applications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Endothelial cells, fibroblasts, and immune cells are the three main cell types which appear in most cancers and are vital components in enhancing the drug resistance of tumors [103, 114-120].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [103]
In the citing paper
“Vasculature plays an essential role in the growth and metastasis of malignant tumors [103].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [103]
In the citing paper
“Endothelial cells, fibroblasts, and immune cells are the three main cell types which appear in most cancers and are vital components in enhancing the drug resistance of tumors [103, 114-120].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [103]
Citations
Cites
Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism
Kresge, C. T., Leonowicz, M. E., Roth, W. J., Vartuli, J. C., & Beck, J. S. (1992) · Nature · doi:10.1038/359710a0 · Cited by 16,275
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Chemistry and Properties of Nanocrystals of Different Shapes
Burda, C., Chen, X., Narayanan, R., & El-Sayed, M. A. (2005) · Chemical Reviews · doi:10.1021/cr030063a · Cited by 7,230
Understanding biophysicochemical interactions at the nano–bio interface
Nel, A. E., Mädler, L., Velegol, D., Xia, T., Hoek, E. M. V., Somasundaran, P., Klaessig, F., Castranova, V., & Thompson, M. (2009) · Nature Materials · doi:10.1038/nmat2442 · Cited by 7,083
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Stimuli-responsive nanocarriers for drug delivery
Mura, S., Nicolas, J., & Couvreur, P. (2013) · Nature Materials · doi:10.1038/nmat3776 · Cited by 6,289
New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier
Makadia, H. K., & Siegel, S. J. (2011) · Polymers · doi:10.3390/polym3031377 · Cited by 4,816
Research works printed but not linked: 29
- Aruna U., 2013, Inter. J. Inn. Pharm. Res., 4, 318
- Langer R., 1998, Nature, 392, 5
- Petre C. E., 2007, Int. J. Nanomed., 2, 277
- Lao J., 2013, J. Drug Delivery, 456409
- Saif M. W., 2007, JOP, 8, 166
- Matsumura Y., 1986, Cancer Res., 46, 6387
- Xu G., 2001, Clin. Cancer Res., 7, 3314
- 10.1016/j.addr.2012.09.008 · doi:10.1016/j.addr.2012.09.008 · Paper page
- Pundir S., 2013, Int. J. Drug Res. Technol., 3, 12
- 10.1021/jp077468 · doi:10.1021/jp077468
- Mohanraj V. J., 2006, J. Pharm. Res., 5, 561
- Ma Y. D., 2011, Int. J. Nanomed., 6, 2679
- 10.1002/(SICI)1097-4636(199908)46:2<236::AID-JBM13>3.0.CO;2-F · doi:10.1002/(sici)1097-4636(199908)46:2<236::aid-jbm13>3.0.co;2-f
- Krishna R., 2000, Eur. J. Cancer Sci., 11, 265
- Kettiger H., 2013, Int. J. Nanomed., 8, 3255
- Yuan F., 1995, Cancer Res., 55, 3752
- Jain R. K., 1987, Cancer Res., 47, 3039
- 10.1021/nn900002m · DOI · Paper page
- Chidambaram M., 2012, Int. J. Pharm. Sci., 2, 117
- 10.1039/C1CS15237H · DOI · Paper page
- 10.1038/nnano.2007.223 · DOI · Paper page
- Mohanraj V. J., 2006, Trop. J. Pharm. Res., 5, 561
- Hong R. L., 1999, Clin. Cancer Res., 5, 3645
- Shamsipour F., 2009, Avicenna J. Med. Biotechnol., 1, 27
- Park J. W., 2002, Clin. Cancer Res., 8, 1172
- Uppada S. B., 2014, Int. J. Nanomed., 9, 43
- Bangham A. D., 1965, J. Mol. Biol., 13, 227
- Mueller C., 1994, Methods Cell Sci., 16, 183
- 10.1016/j.cbpa.2005.10.005 · DOI
Cited by
Items 901–1,000 of 1,005
Gao, Y., Wong, K. Y., Ahiabu, A., & Serpe, M. J. (2016) · Journal of Materials Chemistry B · doi:10.1039/c6tb00864j · Cited by 34
Dual pH-Mediated Mechanized Hollow Zirconia Nanospheres
Wang, M., Gong, G., Feng, J., Wang, T., Ding, C., Zhou, B., Jiang, W., & Fu, J. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b07603 · Cited by 32
Huo, S., Chen, S., Gong, N., Liu, J., Li, X., Zhao, Y., & Liang, X. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00488 · Cited by 34
Tannic acid-based sustained-release system for protein drugs
Utatsu, K., Motoyama, K., Nakamura, T., Onodera, R., & Higashi, T. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123229 · Cited by 31
Wang, D., Sha, L., Chen, X., Huang, Y., Tang, C., Xu, T., Li, X., Di, D., Liu, J., & Li, Y. (2022) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2022.112448 · Cited by 34
Drug Delivery Nano-Platforms for Advanced Cancer Therapy
Naumenko, E., Guryanov, I., & Gomzikova, M. O. (2024) · Scientia Pharmaceutica · doi:10.3390/scipharm92020028 · Cited by 38
“Various types of drug nanoformulations have been created by researchers and are already undergoing clinical trials [33], however, each specific case of a disease and a specific drug requires its own delivery systems, their modifications for better targeting certain cancer cells, and therefore this…”
BackgroundDeng, X., Zhang, Z., Ren, T., & Chen, L. (2025) · Cancer Nanotechnology · doi:10.1186/s12645-025-00342-1 · Cited by 38
“(Lei et al. 2017; Li et al. 2016a; Sun et al. 2014b; Wang et al. 2014).”
Nanopharmaceuticals: Tiny challenges for the environmental risk assessment of pharmaceuticals
Berkner, S., Schwirn, K., & Voelker, D. (2015) · Environmental Toxicology and Chemistry · doi:10.1002/etc.3039 · Cited by 31
“, slow release formulations) Zinostatin stimalamer (zinostatin) [19] Genexol-PM (phase II), (methoxy-PEGpolylactic acid/paclitaxel) CRLX101 (phase I/II), (camptothecin linked to beta-cyclodectrin/PEG polymer)”
BackgroundInfluentialAn, S. Y., Hong, S. H., Tang, C., & Oh, J. K. (2016) · Polymer Chemistry · doi:10.1039/c6py00914j · Cited by 31
Antigen-specific T cell Redirectors: a nanoparticle based approach for redirecting T cells
Schütz, C., Varela, J. C., Perica, K., Haupt, C., Oelke, M., & Schneck, J. P. (2016) · Oncotarget · doi:10.18632/oncotarget.11785 · Cited by 34
“Furthermore, antibodies and antibody like complexes have an extremely short in vivo half-life [18–20], whereas 10-200nm particles demonstrate prolonged blood circulation times [21–24].”
A novel approach for targeted delivery to motoneurons using cholera toxin-B modified protocells
Porras, M. A. G., Durfee, P. N., Gregory, A., Sieck, G. C., Brinker, C. J., & Mantilla, C. B. (2016) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2016.09.003 · Cited by 34
“…drug delivery systems hold the promise of precise administration of therapeutic cargos to specific cells or tissues, sparing collateral damage to non-targeted cells/tissues and potentially overcoming multiple drug resistance mechanisms (Bertrand et al., 2014; Sun et al., 2014; Tarn et al., 2013).”
BackgroundGao, Y., & Dong, C. (2017) · Polymer Chemistry · doi:10.1039/c6py01929c · Cited by 32
De, A., Kuppusamy, G., & Karri, V. V. S. R. (2017) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2017.09.059 · Cited by 31
Basova, T., Hassan, A., & Morozova, N. (2019) · Coordination chemistry reviews · doi:10.1016/j.ccr.2018.09.005 · Cited by 25
Su, Z., Xu, Y., Wang, Y., Shi, W., Han, S., & Shuai, X. (2019) · Biomaterials Science · doi:10.1039/c9bm00825j · Cited by 32
Xiao, Y., Xiang, C., Li, S., Mao, C., Chen, H., Chen, J., Tian, S., Cui, X., Wan, Y., Huang, Z., et al. (2020) · Small · doi:10.1002/smll.202002672 · Cited by 31
Gao, J., Qiao, Z., Liu, S., Xu, J., Shi, W., Yang, X., Wang, X., & Tang, R. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.04.008 · Cited by 34
Perveen, M., Noreen, L., Waqas, M., Mehmood, R. F., Javed Iqbal, M., Manzoor, S., Nazir, S., Shawky, A. M., & Khera, R. A. (2023) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2023.108537 · Cited by 33
Yu, J., Zhou, Y., Chen, W., Ren, J., Zhang, L., Lu, L., Luo, G., & Huang, H. (2015) · Materials · doi:10.3390/ma8105332 · Cited by 31
“It can form micelles or self-assembled nanoparticles via the intra- and/or intermolecular interactions of hydrophobic domain in aqueous medium [7–10].”
BackgroundXu, L., Wang, Y., Wei, G., Feng, L., Dong, S., & Hao, J. (2015) · Biomacromolecules · doi:10.1021/acs.biomac.5b01372 · Cited by 31
Guan, M., Li, J., Jia, Q., Ge, J., Chen, D., Zhou, Y., Wang, P., Zou, T., Zhen, M., Wang, C., et al. (2016) · Advanced Healthcare Materials · doi:10.1002/adhm.201600402 · Cited by 31
Lai, H., Lu, M., Lu, H., Stenzel, M. H., & Xiao, P. (2016) · Polymer Chemistry · doi:10.1039/c6py01188h · Cited by 31
Lai, X., Tan, L., Deng, X., Liu, J., Li, A., Liu, J., & Hu, J. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b14681 · Cited by 31
Loya-Castro, M. F., Sánchez-Mejía, M., Sánchez-Ramírez, D. R., Domínguez-Ríos, R., Escareño, N., Oceguera-Basurto, P. E., Ochoa, E. B. F., Ramos, A. Q., Toro‐Arreola, A. D., Topete, A., et al. (2018) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2018.02.013 · Cited by 33
HPMA‐Based Nanocarriers for Effective Immune System Stimulation
Kramer, S., Langhanki, J., Krumb, M., Opatz, T., Bros, M., & Zentel, R. (2019) · Macromolecular Bioscience · doi:10.1002/mabi.201800481 · Cited by 30
Cao, S., Shao, J., Xia, Y., Che, H., Zhong, Z., Meng, F., van Hest, J. C. M., Abdelmohsen, L. K. E. A., & Williams, D. S. (2019) · Small · doi:10.1002/smll.201901849 · Cited by 36
Self-citationOwais, M., Faisal, S. M., Ahmad, N., Rauf, M. A., Umar, M. S., Mujeeb, A., Pachauri, P., Ahmed, A., Kashif, M., Ajmal, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-48180-7 · Cited by 33
Xing, Y., Peng, A., Yang, J., Cheng, Z., Yue, Y. S., Liu, F., Li, F., Liu, Y., & Liu, Q. (2024) · Advanced Science · doi:10.1002/advs.202309583 · Cited by 39
Yuan, Z., Li, Y., Sun, M., Yuan, M., Han, Z., Li, X., Liu, S., Sun, Y., Cao, J., & Fan, L. (2025) · Theranostics · doi:10.7150/thno.106991 · Cited by 35
“Another issue is the immunogenicity of nanoparticles, as their presence in the body may trigger immune responses, leading to inflammation or exacerbating existing CVDs conditions [55].”
González‐Ayón, M. A., Sañudo‐Barajas, J. A., Picos‐Corrales, L. A., & Licea‐Claveríe, A. (2015) · Journal of Polymer Science Part A Polymer Chemistry · doi:10.1002/pola.27766 · Cited by 31
Perillo, E., Porto, S., Falanga, A., Zappavigna, S., Stiuso, P., Tirino, V., Desiderio, V., Papaccio, G., Galdiero, M., Giordano, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6013 · Cited by 30
“Nanotechnology has the potential to promote delivery of drugs improving specificity and enhancing the uptake [28–30].”
BackgroundChakraborty, I., & Mascharak, P. K. (2016) · Microporous and Mesoporous Materials · doi:10.1016/j.micromeso.2016.07.028 · Cited by 31
Crystalline assembly of gold nanoclusters for mitochondria targeted cancer theranostics
Basu, S., Goswami, U., Paul, A., & Chattopadhyay, A. (2018) · Journal of Materials Chemistry B · doi:10.1039/c7tb03254d · Cited by 32
He, H., Zhou, J., Liu, Y., Liu, S., Xie, Z., Yu, M., Wang, Y., & Shuai, X. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b00194 · Cited by 30
Esnaashari, S. S., & Amani, A. (2018) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-018-9318-0 · Cited by 31
Photothermal effects on protein adsorption dynamics of PEGylated gold nanorods
Polo, E., Araban, V., Pelaz, B., Álvarez, A., Taboada, P., Mahmoudi, M., & del Pino, P. (2019) · Applied Materials Today · doi:10.1016/j.apmt.2019.04.013 · Cited by 30
Polymeric Micelles with Reduction-Responsive Function for Targeted Cancer Chemotherapy
Wan, D., Li, C., & Pan, J. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.9b01070 · Cited by 30
Immunotherapy against Prion Disease
Ma, Y., & Ma, J. (2020) · Pathogens · doi:10.3390/pathogens9030216 · Cited by 34
Recent progress in nanotechnology based ferroptotic therapies for clinical applications
Xu, Y., Qin, Z., Ma, J., Cao, W., & Zhang, P. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173198 · Cited by 30
Shcharbin, D., Bryszewska, M. J., Mignani, S. M., Shi, X., & Majoral, J. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112788 · Cited by 30
A novel pH-responsive Fe-MOF system for enhanced cancer treatment mediated by the Fenton reaction
Wang, S., Wu, H., Sun, K., Hu, J., Chen, F., Liu, W., Chen, J., Sun, B., & Hossain, A. M. S. (2021) · New Journal of Chemistry · doi:10.1039/d0nj05105e · Cited by 33
Ferritin nanocages for early theranostics of tumors via inflammation-enhanced active targeting
Jiang, B., Jia, X., Ji, T., Zhou, M., He, J., Wang, K., Tian, J., Yan, X., & Fan, K. (2021) · Science China Life Sciences · doi:10.1007/s11427-021-1976-0 · Cited by 31
“…link.springer.com SCIENCE CHINA Life Sciences †Contributed equally to this work *Corresponding authors (Jie Tian, email: jie.tian@ia.ac.cn; Xiyun Yan, email: yanxy@ibp.ac.cn; Kelong Fan, email: fankelong@ibp.ac.cn) blood vessels (tumor-mediated EPR effect) (Greish, 2010; Sun et al., 2014).”
BackgroundMethodAyala-Fuentes, J. C., Gallegos-Granados, M. Z., Villarreal-Gómez, L. J., Antunes‐Ricardo, M., Grande, D., & Chávez-Santoscoy, R. A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14050888 · Cited by 33
“but at a reduced rate relative to a positively charged surface—the lesser the opsonization, the greater the efficiency of accumulation in tumors [23].”
BackgroundJiang, Y., Zhou, H., Zhao, W., & Zhang, S. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c00409 · Cited by 30
Xing, Y., Yang, J., Wang, Y., Wang, C., Pan, Z., Liu, F.-L., Liu, Y., & Liu, Q. (2023) · ACS Nano · doi:10.1021/acsnano.2c12107 · Cited by 31
Toxicity evaluation of silica nanoparticles for delivery applications
Tan, Y., Yu, D., Feng, J., You, H., Bai, Y., He, J., Cao, H., Che, Q., Guo, J., & Su, Z. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-023-01312-z · Cited by 30
Wang, S., Deng, H., Huang, P., Sun, P., Huang, X., Su, Y., Zhu, X., Shen, J., & Yan, D. (2016) · RSC Advances · doi:10.1039/c5ra24273h · Cited by 31
Recent Advances in Nanotechnology for the Treatment of Dry Eye Disease
Coco, G., Buffon, G., Taloni, A., & Giannaccare, G. (2024) · Nanomaterials · doi:10.3390/nano14080669 · Cited by 32
Kim, J., Yoon, H., Viswanath, S., & Dağdeviren, C. (2025) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-020524-121438 · Cited by 37
Bioresponsive engineered nanoparticles for immunomodulation
Hegde, M., Mishra, A., Banerjee, R., Bintee, B., Alqahtani, M. S., Abbas, M., Shanmugam, M. K., Drum, C. L., Sethi, G., Liu, L., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04305-6 · Cited by 35
“A key limitation of ultrasound-respon-sive DDSs is the low sonosensitivity of small nanocar-riers ( 250 nm), which favours stability but weakens ultrasound response [418, 423].”
Zhou, Q., Xu, L., Liu, F., & Zhang, W. (2016) · Polymer · doi:10.1016/j.polymer.2016.04.056 · Cited by 28
Paul, M., Sarkar, K., Deb, J., & Dastidar, P. (2017) · Chemistry - A European Journal · doi:10.1002/chem.201605674 · Cited by 29
Predicting the impact of structural diversity on the performance of nanodiamond drug carriers
Barnard, A. S. (2018) · Nanoscale · doi:10.1039/c8nr01688g · Cited by 30
Self-Assembled Nanogels: From Particles to Scaffolds and Membranes
Kankala, R. K., Wang, S., Chen, A., & Zhang, Y. S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813339-2.00002-5 · Cited by 38
Self-citationZhang, J., Wang, Q., Liu, J., Guo, Z., Yang, J., Li, Q., Zhang, S., Yan, C., & Zhu, W. (2019) · ACS Applied Bio Materials · doi:10.1021/acsabm.8b00812 · Cited by 29
Zhu, J., Zhang, H., Chen, K., Yu, H., Yang, Z., Chen, S., Zheng, X., Zhou, X. H., & Jiang, Z. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201901331 · Cited by 29
Functionalization of bismuth sulfide nanomaterials for their application in cancer theranostics
Wang, H., Yang, J., Cao, P., Guo, N., Li, Y., Zhao, Y., Zhou, S., Ouyang, R., & Miao, Y. (2020) · Chinese Chemical Letters · doi:10.1016/j.cclet.2020.05.003 · Cited by 29
Self healing hydrogels: A new paradigm immunoadjuvant for delivering peptide vaccine
Gupta, D., Gangwar, A., Jyoti, K., Jyothi, V. G. S. S., Sodhi, R. K., Mehra, N. K., Singh, S. B., & Madan, J. (2020) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2020.111171 · Cited by 30
Singh, S. K., Gordetsky, J., Bae, S., Acosta, E. P., Lillard, J. W., & Singh, R. (2020) · Cells · doi:10.3390/cells9091976 · Cited by 29
“To circumvent drug delivery limitations, nanoparticles (NPs) have been developed to advance disease detection, diagnosis, and the targeted delivery of drugs [25,26].”
Improved Cancer Targeting by Multimerizing Aptamers on Nanoscaffolds
Omer, M., Andersen, V. L., Nielsen, J. S., Wengel, J., & Kjems, J. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.10.013 · Cited by 29
“Another promising approach has been to use nanoparticles to display a large number of aptamers;(12) however, nanoparticles suffer from biocompatibility issues, including uncontrolled liver retention, passive retention, as well as contamination from their synthesis.(13) As a result, there is an unmet need to establish…”
BackgroundChen, X., Xie, B., Huang, L., Wan, J., Wang, Y., Shi, X., Qiao, Y., Song, H., & Wang, H. (2021) · Theranostics · doi:10.7150/thno.55250 · Cited by 31
“To date, the success of these innovations has resulted in many nanosystems reaching clinical trials, and some of them have garnered FDA approval for human use [3, 4].”
BackgroundSun, C., Gao, S., Tan, Y., Zhang, Z., & Xu, H. (2021) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c00254 · Cited by 30
Dong, Y., Li, W., Gu, Z., Xing, R., Ma, Y., Zhang, Q., & Liu, Z. (2019) · Angewandte Chemie · doi:10.1002/ange.201904860 · Cited by 29
Manna, K., Patra, P., Roy, A., Roy, R. K., Sunka, K. C., Dhara, S., Patra, N., & Pal, S. (2022) · ACS Applied Polymer Materials · doi:10.1021/acsapm.2c00393 · Cited by 29
Wu, X., Wang, L., Xu, Y., Chen, J., Luo, K. Q., Yuan, M., Li, J., Yuan, G., Gu, Z., Jia, X., et al. (2022) · Small · doi:10.1002/smll.202200522 · Cited by 31
Nanoscale metal–organic frameworks as photosensitizers and nanocarriers in photodynamic therapy
Matlou, G. G., & Abrahamse, H. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.971747 · Cited by 34
“This has promoted their use as delivery vehicles of therapeutic agents (photosensitizers, target ligands, or therapy drugs) in cancer therapy (Sun et al., 2014).”
BackgroundFlavonoid-based nanomedicines to target tumor microenvironment
Talib, W. H., Abuawad, A., Thiab, S. H., Alshweiat, A., & Mahmod, A. I. (2022) · OpenNano · doi:10.1016/j.onano.2022.100081 · Cited by 30
Supramolecular nanoscale assemblies for cancer diagnosis and therapy
Coelho, S. C., Pereira, M. D. C., Juzeniene, A., Juzenas, P., & Coelho, M. A. N. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.06.034 · Cited by 33
Dasargyri, A., Hervella, P., Christiansen, A. J., Proulx, S. T., Detmar, M. J., & Leroux, J. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.021 · Cited by 30
Kopp, M., Rotan, O., Papadopoulos, C., Schulze, N., Meyer, H. H., & Epple, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178260 · Cited by 30
The Implications and Future Perspectives of Nanomedicine for Cancer Stem Cell Targeted Therapies
Singh, V. K., Saini, A., & Chandra, R. (2017) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2017.00052 · Cited by 31
Xu, W., Zhang, Y., Gao, Y., & Serpe, M. J. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b04053 · Cited by 30
Self-citationXin, J., Zhang, K., Huang, J., Luo, X., Gong, X., Yang, Z., Lin, H., Shan, H., & Gao, J. (2019) · Biomaterials Science · doi:10.1039/c8bm01039k · Cited by 29
Delineating the tumor margin with intraoperative surface-enhanced Raman spectroscopy
Jiang, C., Wang, Y., Song, W., & Lu, L. (2019) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-019-01577-9 · Cited by 33
Jiang, W., Huang, L., Mo, F., Zhong, Y., Xu, L., & Fu, F. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb00109c · Cited by 29
Shell cross-linked polymeric micelles as camptothecin nanocarriers for anti-HCV therapy
Jiménez‐Pardo, I., González‐Pastor, R., Lancelot, A., Claveria‐Gimeno, R., Velázquez‐Campoy, A., Abian, O., Ros, M. B., & Sierra, T. (2015) · Macromolecular Bioscience · doi:10.1002/mabi.201500094 · Cited by 28
Molecular and nanoparticulate agents for photodynamic therapy guided by near infrared imaging
Grebinyk, A., Chepurna, O. M., Frohme, M., Qu, J., Patil, R., Vretik, L. O., & Ohulchanskyy, T. Y. (2024) · Journal of Photochemistry and Photobiology C Photochemistry Reviews · doi:10.1016/j.jphotochemrev.2024.100652 · Cited by 34
Ligand Lipophilicity Determines Molecular Mechanisms of Nanoparticle Adsorption to Lipid Bilayers
Huang-Zhu, C. A., Sheavly, J. K., Chew, A. K., Patel, S. J., & Lehn, R. C. V. (2024) · ACS Nano · doi:10.1021/acsnano.3c11854 · Cited by 29
Nair, J. B., Mohapatra, S., Ghosh, S., & Maiti, K. K. (2014) · Chemical Communications · doi:10.1039/c4cc09829c · Cited by 28
Xu, S., Li, Y., Xiang, Y., Deng, H., Deng, L., Fan, H., Tang, H., Zhang, J., & Dong, A. (2016) · Macromolecular Bioscience · doi:10.1002/mabi.201600076 · Cited by 28
Challenges in modelling nanoparticles for drug delivery
Barnard, A. S. (2015) · Journal of Physics Condensed Matter · doi:10.1088/0953-8984/28/2/023002 · Cited by 31
Torino, E., Aruta, R., Sibillano, T., Giannini, C., & Netti, P. A. (2016) · Scientific Reports · doi:10.1038/srep32727 · Cited by 32
Biswas, D., An, S. Y., Li, Y., Wang, X., & Oh, J. K. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b01146 · Cited by 28
van der Meer, S. B., Knuschke, T., Frede, A., Schulze, N., Westendorf, A. M., & Epple, M. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.05.049 · Cited by 33
Current state and prospects of nano-delivery systems for sorafenib
Khan, M. A., Raza, A., Ovais, M., Sohail, M. F., & Ali, S. (2018) · International Journal of Polymeric Materials · doi:10.1080/00914037.2018.1429434 · Cited by 29
“Chemotherapeutic agents have potential to work best against cells in exponential phase, hence killing non-specifically cancerous as well as normal cells, which is a main problem with chemotherapeutic agents.([4,5]) Micro-molecule inhibitors against Tyrosine kinases have demonstrated a tremendous improvement in tumor m…”
BackgroundSau, S., Tatiparti, K., Alsaab, H. O., Kashaw, S. K., & Iyer, A. K. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.03.003 · Cited by 30
Advancements in Nanomedicine for Multiple Myeloma
Detappe, A., Bustoros, M. W., Mouhieddine, T. H., & Ghoroghchian, P. P. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.04.005 · Cited by 29
Wang, H., Luo, J., Zhang, Y., He, D., Jiang, R., Xie, X., Yang, Q., Li, K., Xie, J., & Zhang, J. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119301 · Cited by 28
Self-citationPapain bioinspired gold nanoparticles augmented the anticancer potency of 5-FU against lung cancer
Li, T., Yan, G.-Y., Bai, Y., Wu, M., Fang, G., Zhang, M., Xie, Y.-J., Borjigidai, A., & Fu, B. (2020) · Journal of Experimental Nanoscience · doi:10.1080/17458080.2020.1746767 · Cited by 29
Bobde, Y., Biswas, S., & Ghosh, B. (2020) · European Polymer Journal · doi:10.1016/j.eurpolymj.2020.110018 · Cited by 29
Qiu, J., Liu, Y., & Younan Xia, A. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202002031 · Cited by 28
Khani, A., Eskandani, M., Derakhshankhah, H., Soleimani, K., Nakhjavani, S. A., Massoumi, B., Jahanban‐Esfahlan, R., Moloudi, K., & Jaymand, M. (2022) · Journal of Polymer Research · doi:10.1007/s10965-022-03004-7 · Cited by 28
Luo, D., Wang, X., Walker, E., Springer, S. E., Ramamurthy, G., Burda, C., & Basilion, J. P. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c23780 · Cited by 29
Duan, Z., Liang, M., Yang, C., Yan, C., Wang, L., Song, J., Han, L., Fan, Y., Li, W., Liang, T., et al. (2022) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2022.127006 · Cited by 28
Naringin@Metal–Organic Framework as a Multifunctional Bioplatform
Ge, X., Jiang, F., Wang, M., Chen, M., Li, Y., Phipps, J., Cai, J., Xie, J., Ong, J., Dubovoy, V., et al. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c19904 · Cited by 28
Sathyan, A., Deng, L., Loman, T., & Palmans, A. R. A. (2023) · Catalysis Today · doi:10.1016/j.cattod.2023.114116 · Cited by 30
Ma, X., Sun, J., Qiu, C., Wu, Y., Zheng, Y., Yu, M., Pei, X.-W., Wei, L., Niu, Y.-J., Pang, W.-H., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.051 · Cited by 28
Li, C., Xu, L., Liu, Z., Li, Z., Quan, Z., Kheraif, A. A. A., & Lin, J. (2018) · Dalton Transactions · doi:10.1039/c8dt00258d · Cited by 27
Endocytic Selective Toxicity of Rhodamine 6G nanoGUMBOS in Breast Cancer Cells
Bhattarai, N., Mathis, J. M., Chen, M., Pérez, R. L., Siraj, N., Magut, P. K. S., McDonough, K. C., Sahasrabudhe, G., & Warner, I. M. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00339 · Cited by 28
Active targeted drug delivery of MMP-2 sensitive polymeric nanoparticles
Pan, J., Li, P.-J., Wang, Y., Chang, L., Wan, D., & Wang, H. (2018) · Chemical Communications · doi:10.1039/c8cc05504a · Cited by 28
Metadata
- Authors
- Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y.
- Affiliations
- Georgia Institute of Technology (US)
- Venue
- Angewandte Chemie International Edition
- Publisher
- Wiley
- Published
- 2014-10-07
- Volume
- 53
- Issue
- 46
- Pages
- 12320-12364
- ISSN
- 1433-7851 (ISSN-L)
- 1521-3773
- OpenAlex
- W2134726513
- Cited by
- 2,164
- References
- 578
- Citations by year
- 2026: 57 · 2025: 146 · 2024: 163 · 2023: 153 · 2022: 209 · 2021: 200 · 2020: 221 · 2019: 237 · 2018: 257 · 2017: 230 · 2016: 180 · 2015: 109 · 2014: 2
- FWCI
- 11.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Angewandte Chemie International Edition (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
- Keywords
- engineered nanoparticles, drug delivery, cancer therapy, targeted drug delivery, enhanced permeability and retention effect, pH-responsive delivery, tumor-targeting ligands, tissue distribution, circulation half-life, immunogenicity, combination therapy, multidrug resistance, contrast media, theranostics, nanoparticle surface modification
- MeSH terms
- Animals, Antineoplastic Agents, Delayed-Action Preparations, Humans, Neoplasms, Drug Delivery Systems, Nanotechnology, Nanomedicine, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.